ITC Bans Chinese Thyroid Drugs Over Trade Secret Theft
Published Date: 6/4/2025
Notice
Summary
The U.S. International Trade Commission found that several Chinese pharma companies stole trade secrets related to special thyroid medicine. Because of this, these companies can’t import these products into the U.S. for seven years, and they must stop their illegal actions immediately. This decision protects American businesses and keeps the market fair starting now.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Seven-Year Import Ban on Specific Drugs
The Commission issued a seven-year limited exclusion order that bars the unlicensed entry into the United States of certain selective thyroid hormone receptor‑beta agonists, processes for making them, and products containing them when imported by or on behalf of the named Corporate Respondents. The order lasts seven years and is intended to protect American businesses and keep the market fair.
Immediate Cease-and-Desist for Respondents
The named Corporate Respondents (Ascletis Pharma Inc.; Ascletis Pharmaceuticals Co. Ltd.; Ascletis Bioscience Co., Ltd.; and Gannex Pharma Co., Ltd.) are subject to cease and desist orders requiring them to stop their misappropriation and related illegal actions immediately. The orders accompany the limited exclusion order and enforce an immediate stop to the conduct found to violate section 337.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in